Indraprastha Medical Corporation Announces Completion of Independent Director Vinayak Chatterjee's Tenure

1 min read     Updated on 01 Apr 2026, 08:29 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Indraprastha Medical Corporation Limited announced the completion of Mr. Vinayak Chatterjee's tenure as Independent Director on March 31, 2026. He completed his second five-year term on the Board of Directors and ceased to be a Director and Member/Chairperson of respective Board Committees. The company has provided required disclosures to stock exchanges under SEBI regulations.

powered bylight_fuzz_icon
36601149

*this image is generated using AI for illustrative purposes only.

Indraprastha medical corporation Limited has announced the completion of tenure of its Independent Director Mr. Vinayak Chatterjee, marking the end of his second five-year term on the Board of Directors. The healthcare company informed stock exchanges about this board change through a formal intimation dated April 1, 2026.

Director Tenure Completion Details

Mr. Vinayak Chatterjee, holding Director Identification Number (DIN) 00008933, completed his second term of five consecutive years as Independent Director on March 31, 2026. The completion of his tenure resulted in his cessation as Director of the Company and as Member/Chairperson of respective Board Committees at the end of March 31, 2026.

Parameter: Details
Director Name: Mr. Vinayak Chatterjee
DIN: 00008933
Cessation Date: March 31, 2026
Reason: Completion of second five-year term
Position: Independent Director

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The intimation was sent to both BSE Limited and National Stock Exchange of India Limited, providing comprehensive details as required under the relevant SEBI circulars.

The formal communication was signed by Priya Ranjan, AVP - Corporate Affairs & Legal, who serves as the Company Secretary & Compliance Officer. The disclosure included an annexure with detailed information about the cessation, including the reason for change and date of cessation.

About the Company

Indraprastha Medical Corporation Limited operates as Indraprastha Apollo Hospitals with its registered office located at Sarita Vihar, Delhi-Mathura Road, New Delhi. The company holds Corporate Identity Number L24232DL1988PLC030958 and is accredited by Joint Commission International, reflecting its commitment to healthcare quality standards.

Historical Stock Returns for Indraprastha Medical Corporation

1 Day5 Days1 Month6 Months1 Year5 Years
-0.03%-1.37%-0.61%-12.27%+1.68%+613.57%

Who will Indraprastha Medical Corporation appoint as the new Independent Director to replace Mr. Vinayak Chatterjee?

How might the departure of an experienced Independent Director impact the company's strategic decision-making and governance oversight?

Will this board composition change affect Indraprastha Medical Corporation's upcoming expansion plans or capital allocation strategies?

Indraprastha Medical Corporation
View Company Insights
View All News
like19
dislike

Indraprastha Medical Corporation Shareholders Approve Independent Director Appointments Through Postal Ballot

2 min read     Updated on 21 Mar 2026, 10:40 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Indraprastha Medical Corporation Limited successfully completed its postal ballot voting on 20th March, 2026, with shareholders approving all four special resolutions for independent director appointments and re-appointments. The remote e-voting process saw 455 members vote representing 2,33,83,859 shares, with approval rates ranging from 94.09% to 99.94% across the four resolutions. The results strengthen the company's board composition with experienced independent directors for five-year terms.

powered bylight_fuzz_icon
35658606

*this image is generated using AI for illustrative purposes only.

Indraprastha Medical Corporation Limited has successfully concluded its postal ballot voting process, with shareholders approving all four special resolutions related to independent director appointments and re-appointments. The remote e-voting period ended on 20th March, 2026, at 5:00 p.m. (IST), with results announced on 21st March, 2026.

Postal Ballot Overview

The postal ballot process was conducted entirely through remote e-voting, facilitated by National Securities Depository Limited (NSDL). The company had 82,949 shareholders on the record date of 13th February, 2026, with postal ballot notices sent electronically to 74,385 shareholders whose email addresses were registered with the company or depositories.

Voting Details: Information
Record Date: 13th February, 2026
Total Shareholders: 82,949
E-voting Period: 19th February to 20th March, 2026
Scrutinizer: CS Baldev Singh Kashtwal
Participating Members: 455
Total Shares Voted: 2,33,83,859

Director Appointments and Re-appointments

The postal ballot covered four special resolutions, all of which were approved with requisite majority. Three resolutions involved re-appointments of existing independent directors for second terms, while one resolution concerned the appointment of a new independent director.

Resolution Results

Resolution Director Name (DIN) Votes in Favour Votes Against Approval %
Resolution 1: Mr. Salil Singhal (00006629) 2,33,69,360 14,499 99.94%
Resolution 2: Ms. Vineeta Rai (07013113) 2,20,01,841 13,81,975 94.09%
Resolution 3: Ms. Madhumita Ganguli (00676830) 2,22,13,255 11,70,604 94.99%
Resolution 4: Mr. Harsh Pati Singhania (00086742) 2,32,46,634 1,37,225 99.41%

Voting Participation Analysis

The voting process demonstrated strong participation across different shareholder categories. Promoter and promoter group shareholders showed unanimous support for all resolutions, voting 21,442,500 shares in favour across all four resolutions with zero opposition votes.

Shareholder Category Breakdown

  • Promoter and Promoter Group: Held 46,753,000 shares with 45.86% voting participation
  • Public Institutions: Held 2,901,585 shares with 48.03% voting participation
  • Public Non-Institutions: Held 42,018,415 shares with 1.30% voting participation

The overall voting participation stood at 25.51% of outstanding shares, with 455 members casting their votes electronically. No invalid votes were recorded during the process.

Regulatory Compliance and Process

The postal ballot was conducted in compliance with Section 108 and 110 of the Companies Act, 2013, and Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014. CS Baldev Singh Kashtwal served as the scrutinizer, ensuring fair and transparent voting process.

The company published advertisements in Financial Express (English) and Jansatta (Hindi) newspapers on 20th February, 2026, as required under regulatory provisions. The voting results and scrutinizer's report have been made available on the company's website and NSDL's e-voting portal.

Board Composition Enhancement

With the approval of these resolutions, the company has strengthened its board composition with experienced independent directors. The re-appointments ensure continuity in governance, while the new appointment of Mr. Harsh Pati Singhania brings additional expertise to the board. All appointments are for five-year terms, with specific commencement dates ranging from February to June 2026.

Historical Stock Returns for Indraprastha Medical Corporation

1 Day5 Days1 Month6 Months1 Year5 Years
-0.03%-1.37%-0.61%-12.27%+1.68%+613.57%

How will the strengthened board composition with new independent directors impact Indraprastha Medical Corporation's strategic initiatives and expansion plans in the healthcare sector?

What specific expertise does Mr. Harsh Pati Singhania bring to the board that could influence the company's future business direction or market positioning?

Will the enhanced governance structure lead to improved ESG ratings or attract institutional investors to increase their stake in the company?

Indraprastha Medical Corporation
View Company Insights
View All News
like17
dislike

More News on Indraprastha Medical Corporation

1 Year Returns:+1.68%